Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-12-12
2008-10-07
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S293000
Reexamination Certificate
active
07432275
ABSTRACT:
Acid-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
REFERENCES:
patent: 5063227 (1991-11-01), Nomoto et al.
patent: 5064833 (1991-11-01), Ife et al.
patent: 5420135 (1995-05-01), Brown et al.
patent: 5580870 (1996-12-01), Barker et al.
patent: 5616582 (1997-04-01), Barker
patent: 5814630 (1998-09-01), Barker et al.
patent: 5939421 (1999-08-01), Palanki et al.
patent: 6169091 (2001-01-01), Cockerill et al.
patent: 6174889 (2001-01-01), Cockerill et al.
patent: 6207669 (2001-03-01), Cockerill et al.
patent: 6225318 (2001-05-01), Sobolov-Jaynes et al.
patent: 6391874 (2002-05-01), Cockerill et al.
patent: 6395733 (2002-05-01), Arnold et al.
patent: 6413971 (2002-07-01), Arnold et al.
patent: 7074799 (2006-07-01), Bakthavatchalam et al.
patent: 2003/0236280 (2003-12-01), Codd et al.
patent: 2004/0156869 (2004-08-01), Bakthavatchalam et al.
patent: 2005/0215575 (2005-09-01), Bakthavatchalam et al.
patent: 2007/0105865 (2007-05-01), Bakthavatchalam et al.
patent: 0 652 218 (1994-11-01), None
patent: 1229025 (2002-08-01), None
patent: 2345486 (2000-12-01), None
patent: 97/30044 (1997-08-01), None
patent: 98/02434 (1998-01-01), None
patent: 99/01441 (1999-01-01), None
patent: 99/35146 (1999-07-01), None
patent: WO-01/21596 (2001-03-01), None
patent: 01/25218 (2001-12-01), None
patent: WO-02/08221 (2002-01-01), None
patent: WO-02/22601 (2002-03-01), None
patent: WO-03/049702 (2003-06-01), None
patent: WO 03/055848 (2003-07-01), None
patent: WO-03/062209 (2003-07-01), None
patent: WO-03/099284 (2003-12-01), None
patent: WO2004/028440 (2004-04-01), None
Olah et al., The journal of biological chemistry, vol. 276, pp. 11021-11030.
Temple et al., “Synthesis of Potential Antimalarial Agents. II. 6,8-Disubstituted Pyrido[2,3-b]pyrazines,” J. Med. Chem. 11:1216-1218 (1968).
Johansen, M.E. et al., “TRPV1 Antagonists Elevate Cell Surface Populations of Receptor Protein and Exacerbate TRPV-1-Mediated Toxicities in Human Epithelial Cells,” Toxicological Sciences 89(1), 278-286 (2006) (Advance Access publication Aug. 24, 2005).
Thomas, Karen C. et al., “Transient Receptor Potential Vanilloid 1 Agonists Cause Endoplasmic Reticulum Stress and Cell Death in Human Lung Cells,”The Journal of Pharmacology and Experimental Therapeutics321(3), 830-838 (2007).
Bolcskei, Kata et al., “Investigation of the Role of TRPV1 Receptors in acute and chronic nociceptive processes using gene-deficient mice,”Pain117, 368-376 (2005).
Helyes, Zsuzsanna et al., “Role of transient receptor potential vanilloid 1 receptors in endotoxin-induced airway inflammation in the mouse,”Am J Physiol Lung Cell Mol. Physiol. 292(5):L1173-81 (2007).
Banvolgyi, Agnes et al., “Evidence for a novel protective role of the vanilloid TRPV1 receptor in a cutaneous contact allergic dermatitis model,”J Neuroimmunol.169, 86-96 (2005).
Trevisani et al., “Antitussive activity of iodo-resiniferatoxin in guinea pigs,” Thorax 59:769-772 (2004).
Garcia-Martinez et al., “Attenuation of thermal nociception and hyperalgesia by VR1 blockers,” PNAS 99:2374-79 (2002).
Honore et al., “A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a Novel Transient Receptor Potential Type V1 Receptor Antagonist, Relieves Pathophysiological Pain Associated with Inflammation and Tissue Injury in Rats,” J. Pharmacol. Exp. Therap. 314:410-421 (2005).
Ghilardi et al., “Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain,” J. Neuroscience 25(12):3126-31 (2005).
Nagy et al., “The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology,” European J. Pharmacol. 500:351-369 (2004).
Szallasi et al., “Vanilloid Receptor TRPV1 Antagonists as the Next Generation of Painkillers. Are We Putting the Cart before the Horse?” J. Med. Chem. 47(11):2717-2723 (2004).
Xiang, et al., “Effects of airway inflammation on cough response in the guinea pig,” J. Applied Physiol., 85:1847-54 (1998).
Sasaki et al., “Effect of NS-21, an Anticholinergic Drug with Calcium Antagonistic Acitivty, on Lower Urinary Tract Function in a Rat Model of Urinary Frequency,” Int. J. Urol., 4:401-406 (1997).
Bakthavatchalam Rajagopal
Blum Charles A.
Brielmann Harry
Caldwell Timothy M.
DeLombaert Stephane
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
Neurogen Corporation
Rahmani Niloofar
Russett Mark D.
LandOfFree
Carboxylic acid, phosphate or phosphonate substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carboxylic acid, phosphate or phosphonate substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carboxylic acid, phosphate or phosphonate substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4018674